AstraZeneca Award for Advancing Small Cell Lung Cancer Treatment (US)

The AstraZeneca Research Award on Strategies Towards Improving the Treatment of Small Cell Lung Cancer (SCLC) provides funding for translational research aimed at improving the diagnosis, understanding, and treatment of SCLC. The award offers up to US$500,000 over three years to researchers at U.S.-based non-profit academic and research institutions conducting patient-focused studies that address critical gaps in SCLC care.

About the AstraZeneca Research Award

The AstraZeneca Research Award supports innovative research that advances the understanding of Small Cell Lung Cancer (SCLC) and develops new strategies to improve patient outcomes.

SCLC is an aggressive form of lung cancer with limited treatment options and a high rate of disease recurrence. The award encourages translational research that bridges laboratory discoveries with clinical applications to improve diagnosis, treatment, resistance management, and long-term survivorship.

Projects must include research involving SCLC patients and focus on generating findings that can be translated into better clinical care.

Program Objectives

The award aims to:

• Improve the diagnosis of Small Cell Lung Cancer.
• Advance the understanding of SCLC biology.
• Develop innovative treatment strategies.
• Identify biomarkers that improve clinical decision-making.
• Investigate mechanisms of treatment resistance.
• Improve prediction of immunotherapy response.
• Support translational research that benefits patients.
• Enhance long-term survival and quality of life for people with SCLC.

Research Focus Areas

Applicants are encouraged to develop proposals in one or more of the following areas:

Advanced Screening Technologies

• Early detection methods
• Innovative diagnostic technologies
• Improved screening approaches

Biomarker Discovery

• Predictive biomarkers
• Prognostic biomarkers
• Molecular profiling
• Precision medicine approaches

Treatment Resistance Research

• Mechanisms of drug resistance
• Tumor evolution
• Disease progression
• Strategies to overcome therapeutic resistance

Immunotherapy Research

• Predicting patient response to immunotherapy
• Immune biomarkers
• Treatment optimization
• Personalized immunotherapy strategies

Biospecimen-Based Studies

• Tissue analysis
• Blood-based biomarkers
• Longitudinal biospecimen research
• Monitoring disease progression
• Evaluating treatment-related changes

Funding Information

The AstraZeneca Research Award provides:

• Maximum funding: US$500,000
• Project duration: Up to 3 years

Budget Requirements

At least two-thirds of the total funding must directly support scientific research activities.

Allowable expenses include:

• Research costs
• Personnel salaries
• Travel related to the project
• Publication costs
• Limited equipment purchases
• Institutional indirect costs (within program limits)

Eligible Research Activities

Supported activities include:

• Translational cancer research
• Clinical research involving SCLC patients
• Biomarker validation
• Laboratory investigations
• Biospecimen collection and analysis
• Precision oncology studies
• Immunotherapy research
• Molecular characterization
• Resistance mechanism studies
• Patient-centered research

Who is Eligible?

Applicants must meet the following requirements:

• Be affiliated with a non-profit academic or research institution.
• Be conducting research at a U.S.-based institution.
• Researchers at any career stage are eligible.
• Postdoctoral researchers may apply.
• Clinical fellows may apply.
• Include studies involving Small Cell Lung Cancer patients.
• Include a patient or patient advocate as part of the research team.
• Demonstrate the patient advocate’s involvement in research design.

Who is Not Eligible?

Applicants are not eligible if they:

• Are currently receiving funding from another LCRF grant.
• Are applying to another LCRF funding track during the same grant cycle.
• Do not meet the institutional eligibility requirements.
• Fail to include the required patient advocate.

Required Application Documents

Applicants should prepare:

• Letter of Intent (LOI)
• NIH biosketch for the Principal Investigator
• NIH biosketches for co-investigators
• NIH biosketches for other key personnel
• Institutional support letter confirming available research resources
• Full research proposal (if invited)
• Budget and budget justification
• Patient advocate information

Role of the Patient Advocate

A patient or patient advocate is a mandatory member of the research team.

Their role includes:

• Providing patient perspectives during study design.
• Helping improve patient relevance.
• Supporting participant-centered research.
• Strengthening the clinical impact of the proposed study.

How Applications Are Evaluated

Applications are generally assessed based on:

• Scientific quality.
• Innovation.
• Translational potential.
• Clinical relevance.
• Feasibility.
• Patient impact.
• Strength of the research team.
• Appropriate involvement of patient advocates.
• Institutional support.
• Budget justification.

Why This Award Matters

Small Cell Lung Cancer remains one of the most difficult cancers to diagnose and treat effectively.

This research award supports projects that can:

• Improve early diagnosis.
• Identify better biomarkers.
• Personalize treatment.
• Reduce treatment resistance.
• Improve immunotherapy outcomes.
• Advance precision oncology.
• Increase survival rates.
• Enhance quality of life for patients.

How to Apply

Follow these steps to prepare a competitive application:

1. Confirm that your institution meets the eligibility requirements.
2. Develop a translational research proposal focused on SCLC.
3. Include studies involving SCLC patients.
4. Recruit a patient or patient advocate to participate in research design.
5. Prepare NIH biosketches for all required investigators.
6. Submit the Letter of Intent (LOI).
7. If invited, prepare and submit the complete proposal with institutional support documentation.
8. Ensure the proposed budget follows the funding guidelines.

Tips for Preparing a Strong Proposal

• Focus on clinically meaningful outcomes.
• Clearly explain the translational value of the research.
• Include robust patient involvement.
• Demonstrate scientific feasibility.
• Present a realistic project timeline.
• Justify the research budget carefully.
• Highlight innovation and potential clinical impact.

Common Mistakes to Avoid

• Excluding a patient or patient advocate from the research team.
• Submitting an application while applying to another LCRF funding track.
• Requesting funding that does not comply with budget rules.
• Providing incomplete NIH biosketches.
• Failing to demonstrate institutional research support.
• Proposing research unrelated to Small Cell Lung Cancer.
• Omitting studies involving SCLC patients.

Frequently Asked Questions (FAQs)

Who can apply for this award?

Researchers at any career stage, including postdoctoral researchers and clinical fellows, affiliated with U.S.-based non-profit academic or research institutions are eligible.

How much funding is available?

The award provides up to US$500,000 over a period of three years.

What types of research are supported?

The program supports translational research involving SCLC patients, including biomarker discovery, diagnostic technologies, immunotherapy research, treatment resistance studies, and biospecimen-based investigations.

Is patient involvement required?

Yes. Every research team must include a patient or patient advocate who contributes to the research design.

Can researchers currently funded by LCRF apply?

No. Applicants currently receiving LCRF funding or applying to another LCRF funding track in the same grant cycle are not eligible.

What documents are required?

Applicants must submit an LOI with NIH biosketches. Invited applicants must provide a full proposal, institutional support documentation, budget, and other required materials.

How should the grant funds be used?

At least two-thirds of the funding must directly support scientific research activities. Limited funding may also be used for salaries, travel, publications, equipment, and eligible institutional indirect costs.

Conclusion

The AstraZeneca Research Award on Strategies Towards Improving the Treatment of Small Cell Lung Cancer provides a significant opportunity for researchers to advance innovative, patient-centered SCLC research. With funding of up to US$500,000 over three years, the program supports translational studies that improve diagnosis, identify new biomarkers, overcome treatment resistance, and develop more effective therapies, ultimately contributing to better outcomes and survivorship for patients living with Small Cell Lung Cancer.